# Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia

> **NCT07726576** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **University Hospital, Bordeaux** · enrollment: 41 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Venetoclax in association with 3+7 and midostaurin

## Key facts

- **NCT ID:** NCT07726576
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2027-09
- **Final completion:** 2031-12
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07726576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07726576, "Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07726576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*